<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752735</url>
  </required_header>
  <id_info>
    <org_study_id>y (2021)013</org_study_id>
    <nct_id>NCT04752735</nct_id>
  </id_info>
  <brief_title>Endovascular treatmenT for Acute Ischemic Stroke in China</brief_title>
  <acronym>DETECT-China</acronym>
  <official_title>Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective real world registry study, aiming to explore the effectiveness and&#xD;
      safety of endovascular treatment of acute ischemic stroke in a Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score (mRS) 0 to 2</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS)</measure>
    <time_frame>Day 2, 7, 14</time_frame>
    <description>the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day180, 360</time_frame>
    <description>Proportion of patients with modified Rankin Score 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of modified Rankin Score</measure>
    <time_frame>Day 90, 180, 360</time_frame>
    <description>Distribution of modified Rankin Score after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intraparenchymal hemorrhage (PH1 and PH2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of death</measure>
    <time_frame>Day 7</time_frame>
    <description>death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cerebral edema</measure>
    <time_frame>48 hours, 7 days</time_frame>
    <description>edema is determined by middle shift.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Stroke</condition>
  <condition>Endovascular Treatment</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endovascular treatment</intervention_name>
    <description>all enrolled patients must receive endovascular treatment.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients must receive endovascular treatment regardless of the time from onset to&#xD;
        treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥ 18;&#xD;
&#xD;
          -  Ischemic stroke confirmed by head CT or MRI;&#xD;
&#xD;
          -  Patients receiving endovascular treatment;&#xD;
&#xD;
          -  First ever stroke or mRS≤2 after previous disease;&#xD;
&#xD;
          -  Complete and clear pre- and post-operative DSA images are available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Imaging data not qualified for evaluation;&#xD;
&#xD;
          -  Absence of important clinical data;&#xD;
&#xD;
          -  The first 50 patients receiving endovascular treatment in a single centerr.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology, General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui-Sheng Chen, Ph.D.</last_name>
      <phone>+86 13352452086</phone>
      <email>chszh@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

